Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Impulse control and related behaviors in Parkinson's disease with dementia.

Martinez-Martin P, Wan YM, Ray Chaudhuri K, Schrag AE, Weintraub D.

Eur J Neurol. 2020 Feb 11. doi: 10.1111/ene.14169. [Epub ahead of print]

PMID:
32048392
2.

Screening performance of abbreviated versions of the UPSIT smell test.

Joseph T, Auger SD, Peress L, Rack D, Cuzick J, Giovannoni G, Lees A, Schrag AE, Noyce AJ.

J Neurol. 2019 Aug;266(8):1897-1906. doi: 10.1007/s00415-019-09340-x. Epub 2019 May 3.

3.

Can neuroimaging predict dementia in Parkinson's disease?

Lanskey JH, McColgan P, Schrag AE, Acosta-Cabronero J, Rees G, Morris HR, Weil RS.

Brain. 2018 Sep 1;141(9):2545-2560. doi: 10.1093/brain/awy211. Review.

4.

Mild Cognitive Impairment in Parkinson's Disease-What Is It?

Weil RS, Costantini AA, Schrag AE.

Curr Neurol Neurosci Rep. 2018 Mar 10;18(4):17. doi: 10.1007/s11910-018-0823-9. Review.

5.

Assessing cognitive dysfunction in Parkinson's disease: An online tool to detect visuo-perceptual deficits.

Weil RS, Schwarzkopf DS, Bahrami B, Fleming SM, Jackson BM, Goch TJC, Saygin AP, Miller LE, Pappa K, Pavisic I, Schade RN, Noyce AJ, Crutch SJ, O'Keeffe AG, Schrag AE, Morris HR.

Mov Disord. 2018 Apr;33(4):544-553. doi: 10.1002/mds.27311. Epub 2018 Feb 23.

6.

Reply: MRI findings of visual system alterations in Parkinson's disease.

Weil RS, McColgan P, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR.

Brain. 2017 Nov 1;140(11):e70. doi: 10.1093/brain/awx245. No abstract available.

7.

The Cats-and-Dogs test: A tool to identify visuoperceptual deficits in Parkinson's disease.

Weil RS, Pappa K, Schade RN, Schrag AE, Bahrami B, Schwarzkopf DS, Crutch SJ, O'Keeffe AG, Morris HR.

Mov Disord. 2017 Dec;32(12):1789-1790. doi: 10.1002/mds.27176. Epub 2017 Oct 4. No abstract available.

8.

Current concepts and controversies in the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies.

Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM.

F1000Res. 2017 Aug 30;6:1604. doi: 10.12688/f1000research.11725.1. eCollection 2017. Review.

9.

Parkinson disease.

Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE.

Nat Rev Dis Primers. 2017 Mar 23;3:17013. doi: 10.1038/nrdp.2017.13. Review.

PMID:
28332488
10.

Visual dysfunction in Parkinson's disease.

Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR.

Brain. 2016 Nov 1;139(11):2827-2843. doi: 10.1093/brain/aww175. Review.

11.

The prediagnostic phase of Parkinson's disease.

Noyce AJ, Lees AJ, Schrag AE.

J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):871-8. doi: 10.1136/jnnp-2015-311890. Epub 2016 Jan 11. Review.

12.

Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease.

Martinez-Martin P, Leentjens AF, de Pedro-Cuesta J, Chaudhuri KR, Schrag AE, Weintraub D.

Mov Disord. 2016 Mar;31(3):270-9. doi: 10.1002/mds.26522. Epub 2015 Dec 22. Review.

PMID:
26695691
13.

Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study.

Lenderking WR, Mannix S, Petrillo J, Kenney C, Landrian A, Schrag AE.

Qual Life Res. 2015 Aug;24(8):1899-910. doi: 10.1007/s11136-015-0925-7. Epub 2015 Feb 6.

PMID:
25655015
14.

Imaging psychogenic movement disorders.

Mehta AR, Rowe JB, Schrag AE.

Curr Neurol Neurosci Rep. 2013 Nov;13(11):402. doi: 10.1007/s11910-013-0402-z. Review.

15.

The functional neuroimaging correlates of psychogenic versus organic dystonia.

Schrag AE, Mehta AR, Bhatia KP, Brown RJ, Frackowiak RS, Trimble MR, Ward NS, Rowe JB.

Brain. 2013 Mar;136(Pt 3):770-81. doi: 10.1093/brain/awt008.

16.

Coactivation sign in fixed dystonia.

Mehta AR, Rowe JB, Trimble MR, Edwards MJ, Bhatia KP, Schrag AE.

Parkinsonism Relat Disord. 2013 Apr;19(4):474-6. doi: 10.1016/j.parkreldis.2012.10.014. Epub 2012 Nov 30. No abstract available.

17.

Functional (conversion) neurological symptoms: research since the millennium.

Carson AJ, Brown R, David AS, Duncan R, Edwards MJ, Goldstein LH, Grunewald R, Howlett S, Kanaan R, Mellers J, Nicholson TR, Reuber M, Schrag AE, Stone J, Voon V; UK-FNS.

J Neurol Neurosurg Psychiatry. 2012 Aug;83(8):842-50. doi: 10.1136/jnnp-2011-301860. Epub 2012 Jun 3. Review.

PMID:
22661497
18.

Parkin disease: a phenotypic study of a large case series.

Khan NL, Graham E, Critchley P, Schrag AE, Wood NW, Lees AJ, Bhatia KP, Quinn N.

Brain. 2003 Jun;126(Pt 6):1279-92.

PMID:
12764051
19.

The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.

Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, Quinn NP, Rascol O, Stocchi F.

Clin Neuropharmacol. 1998 May-Jun;21(3):169-75.

PMID:
9617508

Supplemental Content

Loading ...
Support Center